Relief Therapeutics Holding AG (RLF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Relief Therapeutics Holding AG (RLF) has a cash flow conversion efficiency ratio of -0.115x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-3.76 Million ≈ $-4.75 Million USD) by net assets (CHF32.63 Million ≈ $41.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Relief Therapeutics Holding AG (RLF) market capitalisation for the company's overall valuation and market capitalisation.
Relief Therapeutics Holding AG - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Relief Therapeutics Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Relief Therapeutics Holding AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Relief Therapeutics Holding AG ranked by their cash flow conversion efficiency. Explore Relief Therapeutics Holding AG cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yooshin Engineering Corporation
KQ:054930
|
0.157x |
|
Reino Capital SA
WAR:RNC
|
0.064x |
|
City Of London Investment Trust
LSE:CTY
|
0.004x |
|
Nsys Co. Ltd.
KQ:333620
|
0.014x |
|
Apex Equity Holdings Bhd
KLSE:5088
|
0.143x |
|
Big Camera Corporation Public Company Limited
BK:BIG
|
-0.016x |
|
Intergis
KO:129260
|
0.005x |
|
Yuanta Securities Korea Co Ltd Preference Shares
KO:003475
|
0.161x |
Annual Cash Flow Conversion Efficiency for Relief Therapeutics Holding AG (2006–2024)
The table below shows the annual cash flow conversion efficiency of Relief Therapeutics Holding AG from 2006 to 2024. View Relief Therapeutics Holding AG (RLF) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF36.66 Million ≈ $46.35 Million |
CHF-2.92 Million ≈ $-3.69 Million |
-0.080x | +76.41% |
| 2023-12-31 | CHF52.23 Million ≈ $66.03 Million |
CHF-17.61 Million ≈ $-22.27 Million |
-0.337x | -103.40% |
| 2022-12-31 | CHF145.42 Million ≈ $183.85 Million |
CHF-24.11 Million ≈ $-30.48 Million |
-0.166x | +15.73% |
| 2021-12-31 | CHF181.53 Million ≈ $229.50 Million |
CHF-35.71 Million ≈ $-45.15 Million |
-0.197x | +27.67% |
| 2020-12-31 | CHF67.04 Million ≈ $84.76 Million |
CHF-18.23 Million ≈ $-23.05 Million |
-0.272x | -419.88% |
| 2019-12-31 | CHF14.30 Million ≈ $18.08 Million |
CHF-748.00K ≈ $-945.67K |
-0.052x | -80.17% |
| 2018-12-31 | CHF21.28 Million ≈ $26.91 Million |
CHF-618.00K ≈ $-781.32K |
-0.029x | +48.15% |
| 2017-12-31 | CHF20.95 Million ≈ $26.48 Million |
CHF-1.17 Million ≈ $-1.48 Million |
-0.056x | +56.88% |
| 2016-12-31 | CHF22.24 Million ≈ $28.11 Million |
CHF-2.89 Million ≈ $-3.65 Million |
-0.130x | +65.57% |
| 2015-12-31 | CHF17.66 Million ≈ $22.32 Million |
CHF-6.66 Million ≈ $-8.42 Million |
-0.377x | -13.81% |
| 2014-12-31 | CHF26.35 Million ≈ $33.31 Million |
CHF-8.73 Million ≈ $-11.04 Million |
-0.331x | +22.01% |
| 2013-12-31 | CHF20.61 Million ≈ $26.06 Million |
CHF-8.76 Million ≈ $-11.08 Million |
-0.425x | -124.58% |
| 2012-12-31 | CHF-2.69 Million ≈ $-3.40 Million |
CHF-4.65 Million ≈ $-5.87 Million |
1.729x | +107.83% |
| 2011-12-31 | CHF464.04K ≈ $586.67K |
CHF-10.24 Million ≈ $-12.95 Million |
-22.075x | -6931.42% |
| 2010-12-31 | CHF52.38 Million ≈ $66.22 Million |
CHF-16.44 Million ≈ $-20.79 Million |
-0.314x | -437.12% |
| 2009-12-31 | CHF56.73 Million ≈ $71.73 Million |
CHF-3.32 Million ≈ $-4.19 Million |
-0.058x | +57.83% |
| 2008-12-31 | CHF68.94 Million ≈ $87.15 Million |
CHF-9.55 Million ≈ $-12.08 Million |
-0.139x | -139.60% |
| 2007-12-31 | CHF64.50 Million ≈ $81.54 Million |
CHF-3.73 Million ≈ $-4.72 Million |
-0.058x | -267.47% |
| 2006-12-31 | CHF66.13 Million ≈ $83.61 Million |
CHF2.28 Million ≈ $2.89 Million |
0.035x | -- |
About Relief Therapeutics Holding AG
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium ph… Read more